Supplementary data

Methylation pattern of the SOCS3 and IL6R promoters in rheumatoid arthritis.

Cieśla M. et al.

Table S1. Genotypes and alleles distribution.

SOCS3 SNPs			Number of carriers (%)							
rs4969168	Allele/	RA RF-positive,	RA RF-negative,	RA ACPA-	RA ACPA-	RA overall,	Controls,	Subjects in a		
	Genotype	n = 82	n = 40	positive,	negative, n=18	n = 122	n = 24	methylation		
				n=104				study, n = 76		
	MAF (A allele)	11%	15%	12.5%	11.1%	12.3%	10.4%	6.6%		
	GG	67 (81.7)	28 (70)	81 (77.9)	14 (77.8)	95 (77.9)	19 (79.2)	66 (86.8)		
	GA	12 (14.6)	12 (30)	20 (19.2)	4 (22.2)	24 (19.7)	5 (20.8)	10 (13.2)		
	AA	3 (3.7)	0	3 (2.9)	0	3 (2.5)	0	0		
rs4969170	Allele/Genotype		•		• • •		•			
	MAF (A allele)	29.9%	35%	30.3%	38.9%	31.6%	45.8%	30.9%		
	GG	41 (50)	17 (42.5)	51 (49)	7 (38.9)	58 (47.5)	7 (29.2)	36 (47.4)		
	GA	33 (40.2)	18 (45)	43 (41.3)	8 (44.4)	51 (41.8)	12 (50)	33 (43.4)		
	AA	8 (9.8)	5 (12.5)	10 (9.6)	3 (16.7)	13 (10.7)	5 (20.8)	7 (9.2)		

Abbreviations: ACPA; Anti-citrullinated protein antibodies; MAF, minor allele frequency; RA, rheumatoid arthritis patients; RF, rheumatoid factor; SNP, single nucleotide polymorphism; *SOCS3*; suppressor of cytokine signaling 3 gene.

Table S2. Distribution of genotypes in a different genetic models between patients and controls.

SOCS3	Model	RA,	Controls,	OR [95% CI]	p-value	Fisher's exact p-value
SNPs		n=122	n=24			
rs4969168	Codominant 1 GG vs. GA	95 (77.9)	19 (79.2) vs. 5 (20.8)	0.96 [0.32-	0.94	0.57
		vs. 24 (19.7)		2.87]		
	Codominant 2 GG vs. AA	95 (77.9)	19 (79.2) vs. 0	nc	1.	0.58
		vs. 3 (2.5)				
	Dominant GA+AA vs. GG	27 (22.1)	5 (20.8) vs. 19 (79.2)	0.93 [0.31-	0.89	0.56
		vs. 95 (77.9)		2.74]		
	Overdominant GA vs. GG+AA	24 (19.7)	5 (20.8) vs. 19 (79.2)	0.93 [0.31-	0.9	0.54
		vs. 98 (80.3)		2.76]		
	Recessive AA vs. GA+GG	3 (2.5)	0 vs. 24 (100)	nc	1.	0.58
		vs. 119 (97.5)				
rs4969170						•
	Codominant 1 GG vs. GA	58 (47.5)	7 (29.2) vs. 12 (50)	0.51 [0.19-	0.19	0.14
		vs. 51 (41.8)		1.42		
	Codominant 2 GG vs. AA	58 (47.5)	7 (29.2) vs. 5 (20.8)	0.31 [0.08-	0.09	0.08
		vs. 13 (10.7)		1.17]		
	Dominant GA+AA vs. GG	64 (52.5)	17 (70.8)	0.45 [0.17-	0.09	0.07
		vs.58 (47.5)	vs. 7 (29.2)	1.18]		
	Overdominant GA vs. GG+AA	51 (41.8)	12 (50) vs. 12 (50)	0.72 [0.3-1.74]	0.46	0.3
		vs. 71 (58.2)				
	Recessive AA vs. GA+GG	13 (10.7)	5 (20.8) vs. 19 (79.2)	0.45 [0.14-	0.19	0.15
		vs. 109 (89.3)		1.43]		

Data are presented as number (%). Abbreviations: CI, confidence interval; OR, odds ratio. For other please refer to Table S1 in supplementary file.

Table S3. Distribution of	genotypes in a different	genetic models between	rheumatoid factor pos	sitive and rheumatoid	factor negative patients.
			I		

SOCS3	Model	RF positive,	RF negative,	OR [95% CI]	p-value	Fisher's exact p-value
SNPs		n=82	n=40			
rs4969168	Codominant 1 GG vs. GA	67 (81.7)	28 (70) vs. 12 (30)	2.39 [0.95-	0.06	0.0504
		vs. 12 (14.6)		6.02]		
	Codominant 2 GG vs. AA	67 (81.7)	28 (70) vs. 0	no	1.	0.36
		vs. 3 (3.7)				
	Dominant GA+AA vs. GG	15 (18.3)	12 (30) vs. 28 (70)	0.52 [0.22-	0.15	0.11
		vs. 67 (81.7)		1.27]		
	Overdominant GA vs. GG+AA	12 (14.6)	12 (30) vs. 28 (70)	0.4 [0.16-1.00]	0.05014	0.0412
		vs. 70 (85.4)				
	Recessive AA vs. GA+GG	3 (3.7)	0 vs. 40 (100)	no	1.	0.30
		vs. 79 (96.3)				
rs4969170				•		
	Codominant 1 GG vs. GA	41 (50)	17 (42.5) vs. 18 (45)	1.32 [0.58-	0.50	0.32
		vs. 33 (40.2)		2.97]		
	Codominant 2 GG vs. AA	41 (50)	17 (42.5) vs. 5 (12.5)	1.51 [0.42-	0.53	0.37
		vs. 8 (9.8)		5.39]		
	Dominant GA+AA vs. GG	41 (50)	23 (57.5)	0.74 [0.34-1.6]	0.44	0.28
		vs. 41 (50)	vs. 17 (42.5)			
	Overdominant GA vs. GG+AA	33 (40.2)	18 (45) vs. 22 (55)	0.82 [0.38-	0.62	0.38
		vs. 49 (59.8)		1.78]		
	Recessive AA vs. GA+GG	8 (9.8)	5 (12.5) vs. 35 (87.5)	0.76 [0.23-	0.65	0.43
		vs. 74 (90.2)		2.51]		

Data are presented as number (%). Abbreviations: please refer to Tables S1 and S2 in supplementary file.

SOCS3	Model	ACPA positive,	ACPA negative,	OR [95% CI]	p-value	Fisher's exact p-value
SNPs		n=104	n=18			
rs4969168	Codominant 1 GG vs. GA	81 (77.9)	14 (77.8) vs. 4 (22.2)	0.86 [0.25-	0.82	0.51
		vs. 20 (19.2)		2.95]		
	Codominant 2 GG vs. AA	81 (77.9)	14 (77.8) vs. 0	no	1.	0.63
		vs. 3 (2.9)				
	Dominant GA+AA vs. GG	23 (22.1)	4 (22.2) vs. 14 (77.8)	0.99 [0.32-	0.99	0.6
		vs. 81 (77.9)		3.09]		
	Overdominant GA vs. GG+AA	20 (19.2)	4 (22.2) vs. 14 (77.8)	0.83 [0.24-	0.77	0.49
		vs. 84 (80.8)		2.84]		
	Recessive AA vs. GA+GG	3 (2.9)	0 vs. 18 (100)	no	1.	0.62
		vs. 101 (97.1)				
rs4969170						
	Codominant 1 GG vs. GA	51 (49)	7 (38.9) vs. 8 (44.4)	0.74 [0.24-	0.58	0.39
		vs. 43 (41.3)		2.23]		
	Codominant 2 GG vs. AA	51 (49)	7 (38.9) vs. 3 (16.7)	0.46 [0.1-2.13]	0.33	0.26
		vs. 10 (9.6)				
	Dominant GA+AA vs. GG	53 (51)	11 (61.1)	0.66 [0.24-	0.42	0.3
		vs. 51 (49)	vs. 7 (38.9)	1.86]		
	Overdominant GA vs. GG+AA	43 (41.3)	8 (44.4) vs. 10 (55.6)	0.88 [0.32-	0.81	0.5
		vs. 61 (58.7)		2.44]		
	Recessive AA vs. GA+GG	10 (9.6)	3 (16.7) vs. 15 (83.3)	0.53 [0.13-	0.4	0.29
		vs. 94 (90.4)		2.19]		

Table S4. Distribution of genotypes in a different genetic models between anti-citrullinated protein antibodies positive and anti-citrullinated protein antibodies negative patients.

Data are presented as number (%). Abbreviations: please refer to Tables S1 and S2 in supplementary file.

Table S5. Genotypes and alleles distribution	
--	--

IL6R					Number of carriers	(%)		
SNPs								
rs4129267	Allele/	RA RF-	RA RF-	RA ACPA-	RA ACPA-	RA overall,	Controls,	Subjects in a
	Genotype	positive,	negative,	positive, n=104	negative, n=18	n = 122	n = 24	methylation
		n = 82	n = 40					study, n = 76
	MAF (T allele)	29.9%	25%	29.8%	19.4%	28.3%	33.3%	30.9%
	CC	43 (52.4)	22 (55)	54 (51.9)	11 (61.1)	65 (53.3)	11 (45.8)	37 (48.7)
	СТ	29 (35.4)	16 (40)	38 (36.5)	7 (38.9)	45 (36.9)	10 (41.7)	31 (40.8)
	TT	10 (12.2)	2 (5)	12 (11.5)	0	12 (9.8)	3 (12.5)	8 (10.5)
rs2228145	Allele/							
	Genotype							
	MAF (C allele)	30.5%	26.3%	30.3%	22.2%	29.1%	31.3%	32.2%
	AA	43 (52.4)	22 (55)	54 (51.9)	11 (61.1)	65 (53.3)	12 (50)	37 (48.7)
	AC	28 (34.1)	15 (37.5)	37 (35.6)	6 (33.3)	43 (35.2)	9 (37.5)	29 (38.2)
	CC	11 (13.4)	3 (7.5)	13 (12.5)	1 (5.6)	14 (11.5)	3 (12.5)	10 (13.2)

Abbreviations: *IL6R*; Interleukin-6 receptor gene. For other please refer to Table S1 in supplementary file.

Table S6. Distribution of genotypes in a different genetic models between patients	and controls.
--	---------------

IL6R SNPs	Model	RA overall,	Controls,	OR (95% CI)	p-value	Fisher's exact p-value
		n=122	n=24			
rs4129267	Codominant 1 CC vs. CT	65 (53.3)	11 (45.8)	0.76 [0.3-1.96]	0.57	0.37
		vs. 45 (36.9)	vs. 10 (41.7)			
	Codominant 2 CC vs. TT	65 (53.3)	11 (45.8)	0.68 [0.16-	0.6	0.42
		vs. 12 (9.8)	vs. 3 (12.5)	2.84]		
	Dominant CT+TT vs. CC	57 (46.7)	13 (54.2)	0.74 [0.31-1.8]	0.5	0.33
		vs. 65 (53.3)	vs. 11 (45.8)			
	Overdominant CT vs.	45 (36.9)	10 (41.7)	0.82 [0.33-	0.66	0.41
	CC+TT	vs. 77 (63.1)	vs. 14 (58.3)	2.01		
	Recessive TT vs. CC+CT	12 (9.8)	3 (12.5)	0.76 [0.2-2.98]	0.7	0.46
		vs. 110 (90.2)	vs. 21 (87.5)			
rs2228145				•		
	Codominant 1 AA vs. AC	65 (53.3)	12 (50)	0.88 [0.34-	0.8	0.49
		vs. 43 (35.2)	vs. 9 (37.5)	2.29]		
	Codominant 2 AA vs. CC	65 (53.3)	12 (50)	0.86 [0.21-	0.84	0.54
		vs. 14 (11.5)	vs. 3 (12.5)	3.53]		
	Dominant AC+CC vs. AA	57 (46.7)	12 (50)	0.88 [0.36-	0.77	0.47
		vs. 65 (53.3)	vs. 12 (50)	2.12]		
	Overdominant AC vs.	43 (35.2)	9 (37.5)	1.1 [0.44-2.75]	0.83	0.5
	AA+CC	vs. 79 (64.8)	vs. 15 (62.5)			
	Recessive CC vs. AA+AC	14 (11.5)	3 (12.5)	0.91 [0.24-	0.89	0.56
		vs. 108 (88.5)	vs. 21 (87.5)	3.48]		

Data are presented as number (%). Abbreviations: please refer to Tables S1, S2 and S5 in supplementary file.

IL6R SNPs	Model	RF positive,	RF negative,	OR [95% CI]	p-value	Fisher's exact p-value
		n=82	n=40			
rs4129267	Codominant 1 CC vs. CT	43 (52.4) vs. 29 (35.4)	22 (55) vs. 16 (40)	1.08 [0.48-	0.85	0.51
				2.42]		
	Codominant 2 CC vs. TT	43 (52.4) vs. 10 (12.2)	22 (55) vs. 2 (5)	0.39 [0.08-	0.22	0.20
				1.99]		
	Dominant CT+TT vs. CC	39 (47.6) vs. 43 (52.4)	18 (45) vs. 22 (55)	1.11 [0.51-	0.79	0.47
				2.39]		
	Overdominant CT vs.	29 (35.4) vs. 53 (64.6)	16 (40) vs. 24 (60)	0.82 [0.37-1.8]	0.62	0.38
	CC+TT					
	Recessive TT vs. CC+CT	10 (12.2) vs. 72 (87.8)	2 (5) vs. 38 (95)	2.64 [0.54-	0.19	0.18
				12.87]		
rs2228145						
	Codominant 1 AA vs. AC	43 (52.4) vs. 28 (34.1)	22 (55) vs. 15 (37.5)	1.05 [0.46-	0.91	0.54
				2.38]		
	Codominant 2 AA vs. CC	43 (52.4) vs. 11 (13.4)	22 (55) vs. 3 (7.5)	0.53 [0.13-	0.35	0.28
				2.16]		
	Dominant AC+CC vs. AA	39 (47.6) vs. 43 (52.4)	18 (45) vs. 22 (55)	1.11 [0.51-	0.79	0.47
				2.39]		
	Overdominant AC vs.	28 (34.1) vs. 54 (65.9)	15 (37.5) vs. 25 (62.5)	0.86 [0.39-	0.72	0.43
	AA+CC			1.91]		
	Recessive CC vs. AA+AC	11 (13.4) vs. 71 (86.6)	3 (7.5) vs. 37 (92.5)	1.91 [0.5-7.38]	0.32	0.26

Table S7. Distribution of genotypes in a different genetic models between rheumatoid factor positive and rheumatoid factor negative patients.

Data are presented as number (%). Abbreviations: please refer to Tables S1, S2 and S5 in supplementary file.

IL6R SNPs	Model	ACPA positive,	ACPA negative,	OR [95% CI]	p-value	Fisher's exact p-value
		n=104	n=18			
rs4129267	Codominant 1 CC vs. CT	54 (51.9)	11 (61.1)	1.11 [0.39-	0.85	0.53
		vs. 38 (36.5)	vs. 7 (38.9)	3.15]		
	Codominant 2 CC vs. TT	54 (51.9)	11 (61.1)	nd		0.13
		vs. 12 (11.5)	vs. 0			
	Dominant CT+TT vs. CC	50 (48.1)	7 (38.9)	1.46 [0.52-	0.47	0.32
		vs. 54 (51.9)	vs. 11 (61.1)	4.09]		
	Overdominant CT vs.	38 (36.5)	7 (38.9)	0.9 [0.32-2.56]	0.85	0.52
	CC+TT	vs. 66 (63.5)	vs. 11 (61.1)			
	Recessive TT vs. CC+CT	12 (11.5)	0 vs. 18 (100)	nd		0.13
		vs. 92 (88.5)				
rs2228145				·		
	Codominant 1 AA vs. AC	54 (51.9)	11 (61.1)	0.8 [0.27-2.37]	0.68	0.45
		vs. 37 (35.6)	vs. 6 (33.3)			
	Codominant 2 AA vs. CC	54 (51.9)	11 (61.1)	0.38 [0.04-3.3]	0.32	0.32
		vs. 13 (12.5)	vs. 1 (5.6)			
	Dominant AC+CC vs. AA	50 (48.1)	7 (38.9)	1.46 [0.52-	0.47	0.32
		vs. 54 (51.9)	vs. 11 (61.1)	4.09]		
	Overdominant AC vs.	37 (35.6)	6 (33.3)	1.1 [0.38-3.22]	0.85	0.54
	AA+CC	vs. 67 (64.4)	vs. 12 (66.7)			
	Recessive CC vs. AA+AC	13 (12.5)	1 (5.6)	2.43 [0.29-	0.36	0.35
		vs. 91 (87.5)	vs. 17 (94.4)	20.24		

Table S8. Distribution of genotypes in a different genetic models between anti-citrullinated protein antibodies positive and anti-citrullinated protein antibodies negative patients.

Data are presented as number (%). Abbreviations: please refer to Tables S1, S2 and S5 in supplementary file.

Figure S1. Linkage disequilibrium between rs4969168 and rs4969170.

Query SNPs:
rs4969168 (chr17:76353793)
rs4969170 (chr17:76360538)
CEU Haplotypes:
rs4969170
A G
A 25 1 26 (0.131)
rs4969168
$G \mid 43 \mid 129 \mid 172 (0.869)$
68 130 198
(0.343) (0.657)
G_G: 129 (0.652)
G_A: 43 (0.217)
A_A: 25 (0.126)
A_G: 1 (0.005)
D': 0.9414
R2: 0.2561
Chi-sq: 50.7121
p-value: <0.0001
rs4969168(A) allele is correlated with rs4969170(A) allele
rs4969168(G) allele is correlated with rs4969170(G) allele

Query SNPs:
rs4129267 (chr1:154426264)
rs2228145 (chr1:154426970)
CEU Haplotypes:
rs2228145
A C
C 129 0 129 (0.652)
rs4129267
$T \mid 0 \mid 69 \mid 69 (0.348)$
129 69 198
(0.652) (0.348)
C_A: 129 (0.652)
T_C: 69 (0.348)
C_C: 0 (0.0)
T_A: 0 (0.0)
D': 1.0
R2: 1.0
Chi-sq: 198.0
p-value: <0.0001
rs4129267(C) allele is correlated with rs2228145(A) allele
rs4129267(T) allele is correlated with rs2228145(C) allele

Figure S2. Linkage disequilibrium between rs4129267 and rs2228145.